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ABSTRACT 
BACKGROUND AND HYPOTHESIS 
Undernutrition is an acquired immunodeficiency with cutaneous anergy to TB 
specific antigens.  Nutritional improvement may be critical for clinical 
response with anti tuberculous therapy. One of the ways that improvement in 
nutrition may lead to clinical recovery is enabling immunological recovery. 
This study examined the relationship between nutritional recovery, changes in 
cell mediated immune response and quality of life. Our hypothesis was that 
there exists an inter relationship between undernutrition, cell mediated 
immunity, clinical improvement and quality of life. Microbiological cure in 
isolation need not represent overall well rounded recovery in a patient at the 
end of therapy. 
 
METHODS 
This was a prospective study designed to include individuals with newly diagnosed 
sputum positive pulmonary Tuberculosis. Anthropometric measurements and 
nutritional assessment was followed by intradermal administration of 0.1ml of 5TU 
strength of PPD (Purified Protein Derivative). This will be read at 48 hours and the 
strength of reaction will be documented. Patients were followed up at 2 months and 6 
months. PPD was re-administered at 6 months. Subgroup analysis and comparison of 
the cohort was done following completion of the six month follow up period. 
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RESULTS  
In this study, about half the patients were found to be anergic (PPD  5mm) at 
baseline. Anergy to PPD was found to be significantly associated with chronic 
energy deficiency at baseline. Most patients had significant weight gain, 
increase in PPD reactivity and improvement in health related quality of life at 6 
months. A small subset of patients had persistent anergy. Persistent anergy was 
also associated with inability to gain weight. Patients who died during the study 
period were more likely to be anergic. However, the causal association between 
anergy and mortality remains unclear. Patients with past history of tuberculosis 
were also more likely to be anergic suggesting a higher risk of recurrence of 
the disease in these patients at a later point of time.  
CONCLUSION 
The overall results do support an inter-relationship between undernutrition, cell 
mediated immunity, clinical improvement and quality of life at baseline and on 
therapy. Undernutrition with poor CMI is associated with an increased risk of 
death. Patients who fail to improve their nutrition on treatment also fail to 
improve their CMI. 
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INTRODUCTION 
Undernutrition has been known to accentuate morbidity and mortality in 
infectious diseases such as tuberculosis(1). Infections with a long incubation 
period and chronic course worsen the nutritional status of the affected 
individuals(2). Undernutrition plays a pivotal role in acquired 
immunodeficiency, affecting both innate and adaptive immune status(3).  
Epidemics of Tuberculosis in the past have been well recognized where poor 
nutritional status has been a key factor perpetuating the former and maintaining 
it in good numbers.  
Despite the widespread use of combination chemotherapy, co-existence of 
malnutrition with high prevalence of tuberculosis poses a great threat to 
economic and overall development in the already strained health resources in 
developing countries(4)(5). Leyton et.al studied the same as early as the 1940s 
among undernourished Russian prisoners of war. This is of scientific and 
historic value as this was one of the first observational studies clearly 
demonstrating the ill-effects of prolonged starvation and subsequent 
malnutrition, which predisposed these individuals to infections such as 
Tuberculosis(1). Recently a strong and consistent log-linear association 
between incidence of Tuberculosis and body mass index has been extensively 
studied. However, there is a dearth of literature establishing the 
pathophysiological mechanisms behind this association.  
A quarter of the global disease burden of tuberculosis is from the Indian 
subcontinent. As per the Revised National Tuberculosis Control Programme 
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(RNTCP – 2015) data, the estimated incidence was 2.8 million cases with 
cause specific mortality of 0.48 million attributed to tuberculosis(6). India is 
also one of the leading nations contributing to global burden of multi drug 
resistant tuberculosis (MDR-TB) as reported by the Global TB Report, 2016 
issued by the World Health Organization. The estimated incidence of MDR 
Tuberculosis is 1.3 lakhs with two-thirds of this being pulmonary 
Tuberculosis(7).  
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AIMS AND OBJECTIVES 
 
AIMS: 
To study the relationship between undernutrition and tuberculin reactivity at 
presentation and in response to TB treatment 
PRIMARY OBJECTIVES: 
1. To study the relationship between tuberculin reactivity and undernutrition in 
newly diagnosed sputum positive pulmonary tuberculosis (HIV negative). 
2. To study the rate of tuberculin conversion in tuberculin negative patients at 
completion of TB treatment. 
3. To study weight gain in underweight patients with sputum positive 
pulmonary TB on treatment. 
4. To correlate weight gain in underweight patients with sputum positive 
pulmonary TB and tuberculin conversion   
SECONDARY OBJECTIVE: 
1. To correlate weight gain and tuberculin conversion to patient assess quality 
of life. 
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REVIEW OF LITERATURE 
INTRODUCTION 
Undernutrition has been known to accentuate morbidity and mortality in 
infectious diseases such as tuberculosis(1). Infections with a long incubation 
period and chronic course worsen the nutritional status of the affected 
individuals(2).  Undernutrition plays a pivotal role in acquired 
immunodeficiency, affecting both innate and adaptive immune status(3).  
Epidemics of Tuberculosis in the past have been well recognized where poor 
nutritional status has been a key factor perpetuating the former and maintaining 
it in good numbers.  
Despite the widespread use of combination chemotherapy, co-existence of 
malnutrition with high prevalence of tuberculosis poses a great threat to 
economic and overall development in the already strained health resources in 
developing countries(4)(5). Leyton et.al studied the same as early as the 1940s 
among undernourished Russian prisoners of war. This is of scientific and 
historic value as this was one of the first observational studies clearly 
demonstrating the ill-effects of prolonged starvation and subsequent 
malnutrition, which predisposed these individuals to infections such as 
Tuberculosis(1). Recently a strong and consistent log-linear association 
between incidence of Tuberculosis and body mass index has been extensively 
studied. However, there is a dearth of literature establishing the 
pathophysiological mechanisms behind this association.  
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BURDEN OF TUBERCULOSIS – INDIAN SCENARIO 
A quarter of the global disease burden of tuberculosis is from the Indian 
subcontinent. As per the Revised National Tuberculosis Control Programme 
(RNTCP – 2015) data, the estimated incidence was 2.8 million cases with 
cause specific mortality of 0.48 million attributed to tuberculosis(6). India is 
also one of the leading nations contributing to global burden of multi drug 
resistant tuberculosis (MDR-TB) as reported by the Global TB Report, 2016 
issued by the World Health Organization. The estimated incidence of MDR 
Tuberculosis is 1.3 lakhs with two-thirds of this being pulmonary 
Tuberculosis(7).  
Tuberculosis–HIV co-epidemic has been a well-recognized entity in Asian and 
African countries. India is also one of the nations with large burden of HIV 
associated tuberculosis. The estimated incidence of HIV associated 
tuberculosis in 2015 was 1.1 lakhs with mortality in more than a third of these 
cases(6).  
 
PATHOPHYSIOLOGY AND NATURAL HISTORY OF 
PULMONARY TUBERCULOSIS 
 
The route of entry of pulmonary tuberculosis is inhalational. Exposure to the 
microbe results in one of the following outcomes: 
- Latent Infection 
- Primary tuberculosis 
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- Reactivation tuberculosis 
- Clearance of Mycobacterium tuberculosis 
 
Roughly a tenth of patients infected with Mycobacterium tuberculosis go on to 
develop active tuberculosis. Primary progressive disease occurs in about fifty 
percent of these patients who develop active disease within the first three years 
following infection(8).  
The microbe gains access to the host through droplets that are up to 10 microns 
in size following which they establish infection in the alveoli if the host’s 
defense system fails to clear the organism. They proliferate in the alveolar 
macrophages that result in the death of these cells. Infected alveolar 
macrophages produce inflammatory cytokines that cause chemotaxis of other 
phagocytes including monocytes. The end result of this process is the 
formation of a granulomatous unit, the tubercle. Failure to further contain the 
process results in enlargement and further recruitment of more inflammatory 
cells causing growth of the tubercle. The bacilli then enter lymph nodes that are 
responsible for drainage of the part of the infected lung.  Draining lymph 
nodes, lymphatic system and affected lung parenchyma result in formation of 
the Ghon’s complex(9). Further proliferation of organism continues till 
mounting of effective cell mediated immune response checks this. However, 
failure of the host’s cell mediated immune system to do so results in further 
destruction of the lung and caseous necrosis. Uncontrolled proliferation of the 
 19 
organism results in bacteremia with subsequent hematogenous spread 
producing disseminated disease. Lesions following bloodstream dissemination 
result in miliary tuberculosis(10). Natural history dictates death of the host 
more often than otherwise. About 20 percent of patients clear the infection and 
recover without treatment or develop chronic infection.  
Reactivation disease is the most common form of tuberculosis. Reactivation of 
tuberculosis occurs in about 10 percent of subjects who develop latent infection 
following initial exposure(11). Immunocompromised individuals, particularly 
those with co-existing advanced HIV infection, chronic kidney disease, 
primary immunodeficiency syndromes, diabetes mellitus with poor glycemic 
control and profound undernutrition are at a much higher risk of reactivation. 
Dormant tubercle bacilli that are seeded during primary infection remain latent 
for years or decades, may undergo reactivation during profound 
immunosuppression. The infection is classically described to involve the apices 
of the lungs. Miliary tuberculosis following reactivation is uncommon, unless 
in the setting of severe immunosuppression(12).  
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IMMUNOLOGY OF PULMONARY TUBERCULOSIS 
 
T cells can be classified into T Helper cells and T cytotoxic cells. T helper cells 
can be further classified based on the profile of the cytokines secreted by them 
into T helper 1 and T helper 2 cells. T helper 1 cells secrete interferon gamma 
and IL-2 whereas Th2 cells produce IL-4, IL-5, IL-6, IL-10 and IL-13(13). Th1 
cells are responsible for humoral immunity and allergic responses. In addition, 
the cytokines produced by a T helper subset seems to propagate the production 
of the same subset and inhibit the production of the other Th subset. 
Differentiation of T helper cells into of these subsets depends on the cytokine 
microenvironment(14). For example, the presence of IL-12 secreted by 
macrophages, results in differentiation of Th cells into Th1 cells and 
production of IFN -. On the contrary, presence of IL-4 results in 
differentiation of T helper cells into Th2 cells. The cytokines produced by Th1 
subset seems to be pro inflammatory whereas those produced by Th2 subset 
seems to be anti-inflammatory. Though the Th1 response in pro-inflammatory, 
this is microbicidal in contrast to the Th2 response. In the presence of excess of 
Th2 response, the microbicidal response of Th1 is suppressed. Cytokines 
studies have demonstrated that there is a shift from predominant Th2 response 
during onset of active tuberculosis to Th1 response as the disease 
progresses(15).  
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ASSOCIATION BETWEEN NUTRITIONAL STATUS AND RISK 
OF TUBERCULOSIS 
 
Undernutrition-tuberculosis co-epidemic is a poorly recognized entity.  This 
calls for attention of medical research as much as the Tuberculosis-HIV co-
epidemic. Better understanding of this entity is of prime importance as the 
vicious cycle of tuberculosis leading to poor nutritional status and 
undernutrition worsening the severity of tuberculosis is crucial for improving 
outcomes of the disease(16). As long as malnutrition continues to remain 
ignored and unrecognized, health programmes will prove to be ineffective in 
elimination of Tuberculosis.  
Observational studies have also shown a strong correlation between body mass 
index and incidence of Tuberculosis(17). Biological basis of this association is 
not well understood or elucidated. A recent study done in South India 
attempted at further elucidation of the same.  The effect of cytokine levels, 
systemic as well as antigen specific cytokines, was studied in individuals with 
latent tuberculosis. Individuals with latent TB were recruited and categorized 
as those with low BMI and normal BMI. Cytokine levels in both groups were 
measured and compared. Individuals with low BMI were noted to have 
uniformly low levels of IFN-γ and TNF-α. The study further went on to show 
that 56 individuals with latent Tuberculosis developed overt disease ten times 
more in the group with low BMI as compared to those with normal BMI. This 
was attributed to the low levels of circulating protective cytokines(18).  
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A study done by Gopalan et al in the early 1950s looked at experimental, 
clinical and epidemiological angles of Tuberculosis malnutrition co-
epidemic(9).  It was noted that deficiency of micronutrients such as Vitamin A 
increased the host’s susceptibility to Tuberculosis. The level of protein in the 
diet, however, did not seem to dictate the susceptibility towards the same. 
These conclusions were drawn based on an experimental model in guinea pigs 
and rats.  It was also noted that animals on high protein diet recovered from the 
negative nitrogen balance following the infection faster than those put on a low 
protein diet. Human subjects with positive nitrogen balance were found to 
rebound more rapidly translating to a better outcome following the disease. 
Hence, it was concluded that high protein diet improved outcomes owing to the 
earlier attainment of positive nitrogen balance. This can be considered as good 
evidence for explaining why an individual with good nutritional status at 
diagnosis has better outcome compared to those that don’t. This brings to the 
light the important understanding that initiation of maintaining a positive 
nitrogen balance need not necessarily start after the disease process has set in. 
While it does not necessarily prevent the disease, it helps quick recovery 
translating to better outcomes in Tuberculosis. 
 Approximately one million new cases of Tuberculosis in India has been 
attributed to undernutrition(19). Reducing adult undernutrition can be an 
effective and a robust strategy containing Tuberculosis in adult population. 
This is perhaps a better strategy than vesting on a nationwide adult vaccination 
programme for Tuberculosis. This can be used as a strategy not only for the 
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infected, but also in individuals who are at higher risk, such as the close 
contacts, HIV affected individuals, patients with chronic kidney disease, etc. 
Many investigators have looked into the role of nutritional supplementation to 
patients receiving anti tubercular therapy and the short and long term outcome 
of these patients(20). However, there is no reliable evidence at present to 
suggest routine nutritional supplementation to standard anti tuberculous 
therapy significantly improves outcome in patients on ATT. Therefore, this 
requires further investigation to fill the grey area in understanding the 
same(21). 
A recent prospective observational study reported by Bhargava et al looked at 
nutritional recovery of 1695 adult patients diagnosed with pulmonary 
tuberculosis in rural central India over a period of five years. Median BMI of 
men at diagnosis was 16.0kg/sqm with a corresponding median weight of 
42.1kg, and that in women were 15.0kg/sqm and 34.1kg respectively. 80% of 
women and 67% of men had moderate to severe undernutrition (corresponding 
to BMI <17.0kg/sqm) at diagnosis. Half of women and a third of men persisted 
to have a BMI less than 17.0kg/sqm at completion of therapy(22). 
Studies have looked into the role of socio-economic factors and nutritional 
status in predicting probability of unfavorable outcomes in patients on 
ATT(23). Adverse outcome in Tuberculosis coexisting with undernutrition has 
been linked to several factors such as increased severity of disease, atypical 
presentation(24), death(25), delayed microbiological clearance, suboptimal 
absorption of drugs, increased incidence of drug related toxicity and 
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relapse(26)(27)(28).  Improvement in quality of life is an important socio-
economic aspect of therapy, one that is often forgotten and overlooked. 
Karyadi et al reported on changes in Karnofsy score, a rating scale of a person's 
ability to perform activities of daily living ranging from 0 (dead) to 100 
(normal).  An improvement in the score from a mean value of 80.2 (at baseline) 
to 97.5 (at completion of therapy) was noted(29). Therefore, it is important 
tonote that subjective improvement in quality of life, as perceived by the 
patient, is one of the most important forces driving them to be compliant to 
therapy.  
Dietary deficiencies of micronutrients and macronutrients significantly change 
immune responses, especially with cell mediated immunity(30). Undernutrition 
has been associated with T-cell development and maturation defects(31). 
Several studies have looked at peripheral blood T-cell profile of children and 
young adults with severe malnutrition. There is a consistent and strong 
correlation noted between degrees of undernutrition and delayed and faulty 
maturation of T-cells. It has also been noted that there is a relative decrease in 
rosette forming T-cells and mature T-cells(32). 
Reduced in vitro function of T-cells has been reported in experimental models 
with deficiency of iron, zinc, copper and Vitamin E(33). Cutaneous anergy to 
mitogens and antigens has been associated with deficiency of amino acids, 
Vitamin A, Vitamin E, pyridoxine, iron and zinc(34). Intriguingly, it has also 
been noted that pyridoxine, ascorbate and biotin deficiencies resulted in 
delayed rejection of grafts(35).  
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CD8 T-cell activity is impaired in zinc, iron and copper deficient murine 
models. The evidence for the aforementioned linking undernutrition to an 
acquired immune-deficient state is mostly from animal models.  
Despite the lack of clear evidence, WHO recommends supplementation of 
micronutrients and macronutrients to patients diagnosed with active 
tuberculosis(36). Because of the bidirectional causal link between 
undernutrition and active tuberculosis, nutritional screening, assessment and 
management are integral components of tuberculosis treatment and care(17). 
This should be in the form of nutrional assessment, nutritional counseling and 
supplementation of micronutrients and macronutrients. However, there are no 
clear guidelines as to how much of augmenting is required as this may vary 
from individual to individual. Patients with undernutrition should be provided 
with locally available nutrient-rich or fortified supplementary foods, as 
necessary to restore normal nutritional status (strong recommendation, very 
low quality evidence)(37). Hence, it is of utmost importance to remember that 
nutritional counseling and supplementation is not an optional intervention, but 
an intergral part of standard practice, which should be implemented world-
wide. However, knowledge of this important aspect among physicians in our 
country is surprisingly low(38).  
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TUBERCULIN SKIN TESTING 
The role of cell mediated immunity in delayed Type IV hypersensitivity 
reaction, which is integral for adequate immune response to Tuberculosis, is 
well elucidated(39). So, it is only logical to conclude that undernutrition can 
lead to inadequate cell mediated immune response and increase a susceptible 
host’s risk of contracting tuberculosis and adversely alter the nature and course 
of the disease. 
Tuberculin Skin test is widely used for the diagnosis of latent Tuberculosis in 
adults in countries with a low prevalence of the disease(40). However, the role 
of this test in diagnosis in countries like India, where the prevalence is high is 
rather limited. However, this test can be used to demonstrate the integrity of 
cell-mediated immune system in individuals.  
Koch first postulated the idea behind this test in 1980(41). However, the 
intradermal technique was described in the early part of the 20thcentury by 
Charles Mantoux(42).  The Tuberculin used most widely is purified protein 
derivative derived from Mycobacterium tuberculosis cultures. The old 
tuberculin is no more used for skin testing. A standardized product called PPD-
S (purified protein derivative prepared as described by Siebert) is used. The 
advantage of this antigen is that the strength is standardized and can be graded 
for administration prior to testing(43). This has resulted in further 
quantification of the result and has also helped improve the reproducibility of 
the test along with graded response obtained with each administration. 
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Intradermal injection of PPD evokes a classical delayed cellular 
hypersensitivity reaction. T-cells, which have previously been sensitized, are 
recruited to the injection site where protective cytokines are released. This 
results in induration through local vasodilation, edema and further recruitment 
of inflammatory cells to the site of inflammation. This reaction is characterized 
by a delayed course, reaching a peak roughly about 48 hours after introduction 
of the antigen(44)(45). The intradermal injection of the antigen causes it to be 
processed by the antigen presenting cells in the skin (i.e. is in a previously 
sensitized individual). Th1 effector cells recognize the antigen and release 
cytokines that act on the vascular endothelium. Recruitment of phagocytes and 
plasma to the site of the injection is seen as erythema and induration(46). The 
ability of a host to elicit this reaction warrants an intact immune system, 
especially those pertaining to cell mediated immunity. Any insult to this arm of 
the immune system will result in the host being unable to mount a response to 
the introduction of the antigen. As mentioned above, undernutrition is 
associated with specific impairment in cell-mediated immunity. Hence, this 
would mean that a patient who is undernourished might be unable to mount an 
adequate response, though he has been exposed adequately to the disease in the 
past. Conversely, patient with good nutrition and an intact cell mediated 
immune system will mount an adequate response to the same dose of the 
antigen with similar prior exposure to the disease. Therefore, reactivity to PPD 
can be used as a surrogate marker of cell mediated immunity(47)(48). 
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The results of the Tuberculin skin test have to be interpreted with caution. The 
person's medical risk factors determine the size of induration (5 mm, 10 mm, or 
15 mm). Formation of vesicles, bullae, lymphadenopathy, ulceration and 
necrosis at the test site should also be diligently noted down. A reaction more 
than just induration (such as ulceration or blistering) indicates high degree of 
tuberculin sensitivity and thus presence of active infection with tubercle 
bacilli.(49) 
Nayme et al conducted a prospective study over a 2 year period which included 
174 patients with confirmed tuberculosis and 205 healthy controls. Using the 
ROC curve, they determined two thresholds of positivity for the Tuberculin 
skin test. 9mm induration had a sensitivity of 68% and specificity of 78%. 
13mm induration was noted to have a sensitivity of 54% and specificity of 
90%. Thus, they concluded that an induration of 9mm (measured at 48 hours) 
after a tuberculin skin test is sufficient to diagnose tuberculosis infection, and 
13mm to diagnose active disease.(50) 
WHO has laid down guidelines on interpretation of the Tuberculin Skin 
Test(51)(42)(52).  
 
‘Induration of 5mm or more is said to be positive in the following situations:’ 
1. ‘HIV positive individual’(53) 
2. ‘Recent contacts of active tuberculosis’(54) 
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3. ‘Persons with nodular or fibrotic changes on Chest X –ray, suggestive of 
Tuberculosis’ 
4. ‘Organ transplant recipients and other individuals on cytotoxic 
immunosuppression’(55) 
5. ‘Patients receiving systemic glucocorticoids for a duration of more than 
six weeks and a dose of prednisolone ≥ 15 mg/day or equivalent.’ 
6. ‘End stage renal disease’(56) 
Induration of 10 mm or more is said to be positive in the following situations 
1. ‘Injectable drug users’ 
2. ‘Residents and employees of high-risk congregate settings such as 
prisons and shelters.’ 
3. ‘Mycobacteriology lab personnel’ 
4. ‘Children less than four years of age, or children and adolescents 
exposed to adults in high-risk categories’ 
5. ‘Infants, children, and adolescents exposed to adults in high-risk 
categories’ 
Induration of 15mm or more is said to be positive in  
1. ‘Persons with no known risk factors for TB. Reactions larger than 15 
mm are unlikely to be due to previous BCG vaccination or exposure to 
environmental mycobacteria.’ 
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ANERGY TO TUBERCULIN SKIN TESTING 
The term anergy was first used by von Pirquet to define an entity different from 
allergy. Both these phenomena were interpreted to be closely associated with 
humoral immunity. The concept of cell mediated immunity was unheard of 
then(57).  Later these were identified to be associated truly with CMI and not 
humoral immunity. Von Pirquet recognized that negative skin tests with 
tuberculin were found during primary tuberculosis, in patients who are 
cachectic, following desensitization with tuberculin, and in healthy individuals, 
years after infection. Conversely, a booster phenomenon was also noted with 
repeat administration in close intervals (less than eight weeks)(58)(59).  
Some people with tuberculosis may have a negative skin test reaction when 
tested years after infection because of a waning response. An initial skin test 
may stimulate (boost) the ability to react to tuberculin. Positive reactions to 
subsequent tests may be misinterpreted as a new infection rather than boosted 
reactions(60). The phenomenon of increased tuberculin reactions upon 
retesting, in the absence of new infection, stems from recall of waned cell 
mediated immunity. Boosting is maximal if the interval between the first and 
second test is less than five weeks. This is much less frequent if the interval is 
more than 60 days(61).  
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IMMUNOLOGIC BASIS OF TUBERCULIN ANERGY 
To further elucidate this pathophysiologic mechanism, studies have looked at 
cytokines secreted by peripheral blood monocytes which are stimulated 
following introduction of PPD injection to the skin(62). It has been noted that 
these monocytes have decreased production of immunoprotective cytokines 
such as IFN-γ and IL-2 that are pivotal in containing Mycobacterial infection. 
These are also essential in formation of functional granulomas(63). Instead, 
there is increased production of immunosuppressive and macrophage 
deactivating cytokines such as IL-10 and TGF-β(64). This Th2 predominant 
response in responsible for anergy to tuberculin noted in a proportion of 
patients with active tuberculosis. Elevated levels of IL-4 and IL-10, with 
concomitantly low levels of IL12 positive cells have been noted in this subset 
of patients with anergy to PPD(65).   
There is evidence beyond doubt that there is a predominant Th2 response in 
patients with active disease at the onset(66).  With progression of disease, it has 
been noted that the cytokines expressed by Th2 predominant response 
involving IL-10 and TGF-β decline. At the same time, patients who were 
anergic to PPD initially mount a positive response with immunological 
recovery and completion of therapy(67). In other words, the balance of this 
immune response shifts from Th1 predominant to a Th2 predominant response. 
This results in paradoxical worsening of lymphadenopathy, lung lesions, 
pleural effusion, tuberculomas and hydrocephalus. The reason behind the 
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innate inability of a patient with active tuberculosis to contain the infection 
would be explained by a predominant Th2 response rather than a Th1 
predominant response(68).  
Various host specific factors such as age, host genetics, cytokine 
microenvironment, dose and localization of inciting antigens, type of antigen 
presenting cells recruited and co-stimulatory molecules are considered 
responsible for this polarization of immunologic response(69)(70). Thus, 
immunological reconstitution and immunological recovery occurs as treatment 
progresses. The timing and appropriateness of this immune recovery 
determines the clinical course of each patient’s recovery(71).  Sudden and 
overwhelming reconstitution would result in clinical worsening, otherwise 
described in literature as paradoxical worsening(72). The clinical recovery 
would be dictated by the integrity of the host’s immune system and the overall 
balance of pro-inflammatory and anti-inflammatory cytokines(73)(74).  
 
ASSOCIATION BETWEEN IMMUNOLOGICAL INTEGRITY 
AND OUTCOME IN TUBERCULOSIS 
There have been numerous observational studies looking at anergy to PPD. An 
interesting account of the phenomenon of TB specific anergy was reported by 
Sousa et al in the mid 90s(75). A study was performed among the Yanomami 
Indians of the Amazonian rain forests in Brazil. This study revealed a very high 
incidence of pulmonary Tuberculosis in these native Indians. What is unique 
about this population is that they remained isolated from contact with the 
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Tubercle bacillus until the middle of the 20th century.  A high prevalence of 
active tuberculosis observed in this population was suggestive of very high 
susceptibility to the disease. To further elucidate this phenomenon, cell-
mediated and humoral immune responses of the natives were compared with a 
control group comprising Brazilians of European descent. A large proportion of 
the Yanomami natives were noted to have cutaneous anergy, compared to the 
controls.  These findings are quite interesting when looked at from the angle of 
human evolution and selection. It might not be too far fetched to conclude that 
the lack of exposure to M. tuberculosis for centuries followed by recent 
exposure has left them handicapped to fight the disease appropriately. 
Conversely, the control group was noted to have a high reactivity to PPD 
suggesting constant exposure to the antigen in the community. It is rather sad 
to note that no mention of the nutritional status of the native Indians or the 
control group has been made in the study.  
Recognized causes of cutaneous anergy include old age, cachexia or 
malnutrition.  Co-existing infections such as measles, intercurrent viral 
illnesses and some bacterial infections may lead to cutaneous anergy(76). In a 
study done on hospitalized patients, Palmer et al found that fever and 
leucocytosis were predictors of cutaneous anergy(77).  It is hypothesized that 
inflammatory cytokines may have an inhibitory effect on delayed type 
hypersensitivity. It is also found to have a preferential activation of Th2 
cellular responses over Th1 response.  
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Patients with proven TB who are show anergy to Tuberculin may be reactive to 
other antigens such as Candida, histoplasmin, tetanus and mumps. 
Immunologic compartmentalization and, suppressor cells are important 
theories giving immunologic basis for this phenomenon. This brings to light 
the important understanding that anergy may be specific or generalized(78).  
There is very little experimental evidence for tuberculosis specific cutaneous 
anergy. Szereday et al looked at the relationship between tuberculin reactivity 
and pattern of T cell profile in patients with tuberculosis. This study involved 
38 patients with culture proven tuberculosis and 22 healthy controls. The 
peripheral T cell profile of these patients was studied along with their reactivity 
to PPD administration. Out of the 38 patients with tuberculosis, 27 showed a 
positive PPD reaction whereas 11 were anergic. All healthy controls mounted a 
positive response following PPD testing. T cell profile showed a change in the 
ratio of gamma-delta T cell subset in those who were anergic to PPD testing. A 
stark difference was noted in patients with positive PPD and healthy controls, 
when compared with the profile in patients with anergy(79). 
Magnani et al suggested that a defective secretion of interferon gamma and a 
lack of skin-selective homing receptor known as cutaneous lymphocyte 
antigen(CLA) is responsible for tuberculosis specific cutaneous anergy in 
patients who are PPD negative.  To prove this hypothesis, they looked at 82 
patients with culture positive tuberculosis. PPD reactivity was studied in all 
patients. 4 out of these showed anergy to PPD. In vitro testing of polyclonal T 
helper cells showed significantly low levels of interferon gamma in these 4 
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patients. PPD anergic patients were also noted to lack the cutaneous leucocyte 
antigen(76).  This brings us to the next important question. Do interferon 
gamma release assays show good correlation to results of PPD testing? 
Interferon gamma release assays mostly go hand in hand with tuberculin skin 
tests. Though there are differences in the sensitivity and specificity of these two 
tests, most patients who show anergy to PPD are also noted to have a negative 
response to IGRA tests(80).  
Gofoma et al conducted a study of PPD skin reactivity in children diagnosed 
with tuberculosis at a tertiary care centre in Nigeria. Of the 97 eligible children 
managed for various forms of TB on whom a Mantoux test was conducted, 82 
(84.5%) had a negative Mantoux reaction and 15 (15.5%) had a positive 
reaction. Malnutrition and HIV infection were significantly associated with a 
negative Mantoux reaction(81).  
A retrospective study by Nagata et al looked at BMI, peripheral blood 
lymphocyte count, serum albumin concentration, and induration size of PPD 
skin test at the time of admission from their clinical charts of all 174 
tuberculosis patients newly admitted in a tertiary care centre in Japan. Based on 
these indices, the nutritional state of tuberculosis patients was divided into 
severely impaired, moderately impaired, mildly impaired or normal.  They 
found that the rate of death from all causes were significantly higher in patients 
who were undernourished at admission. Most patients who met the primary 
outcome (death) were also noted to have anergy to PPD skin testing at 
admission(82). 
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A recent cross-sectional study done by Mellado et al looked at the association 
between nutritional status and PPD reactivity in children with no evidence of 
active Tuberculosis. This study classified children based on their nutritional 
status as per Mc Laren’s classification of protein energy malnutrition. 
Surprisingly, they found no significant difference in the rates of positive PPD 
reactivity among the different groups (classified as per nutritional status). This 
is one of the very few studies which has reported such a result(83). 
Since anergy to PPD is attributable to impairment of Cell Mediated Immunity, 
it is justified in hypothesizing that restoration of CMI (i.e., at completion of 
therapy) should reverse this anergy and cause a positive reaction.  
As mentioned above, there are various theories that have been proposed to 
elucidate the mechanism of anergy to PPD and subsequent reversal of this 
anergy with treatment for tuberculosis. Immunologic compartmentalization is 
one such important immunological hypothesis. To prove this hypothesis, Dieli 
et al studied 6 patients with tuberculosis restricted to body cavities. These 6 
patients included two with tuberculous pleural effusion, one with tuberculous 
peritonitis, one with tuberculous pericarditis and two with tuberculous 
meningitis. All six patients showed a negative reaction to PPD.  Two sets of in 
vitro testing was performed using stimulation of CD4 T cells with 16Da and 
38Da Mycobacterium tuberculosis proteins. First one involved peripheral T 
cell stimulation and the second set involved stimulation of T cells from the 
cavity fluid from the affected site. T cells from blood failed to proliferate 
where as T cells from the cavity fluids showed proliferation when exposed to 
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these antigens. Four months after initiating anti tuberculous therapy, polyclonal 
CD4 T cells were obtained from peirpheral blood and subjected to invitro 
stimulation. This time, they showed good response to the antigenic stimulus. 
All 6 patients also showed reversal of cutaneous anergy. This raises an 
important question. i.e., Could there be a sequestration of CD4 T cells 
associated with tuberculosis specific cell mediated immunity to the sites of 
inflammation, especially in those with a CD4 T cell deficiency? This study, 
though done on a very small number of patients, clearly elucidates the 
hypothesis of immunological compartmentalization. This can be looked at, as a 
a defence mechanism employed by the body to utilize the little available work 
force of cell mediated immunity to contain the progression of the disease 
process(84).  
A prospective observational study done by Delgado et al looked at reversal of 
anergy to PPD in 372 Cambodian patients diagnosed with Tuberculosis.  Of the 
total 372 patients, 138 (37%) acutely ill, HIV negative patients with pulmonary 
tuberculosis were noted to have a negative reaction to PPD soon after 
diagnosis. It is interesting to note that 25 of these 138 individuals had persistent 
anergy to Tuberculin Skin testing after successful completion of anti 
tuberculous therapy(85).   
Tegbaru et al described a similar study looking at CD4 T cell counts in HIV 
negative and positive individuals and its effect on PPD reactivity and 
subsequent conversion after successful therapy in urban Ethiopia.  The overall 
TST reactivity was 66.2% with significantly lower numbers noted in HIV 
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positive individuals (40.5%) as compared to HIV negative individuals (68.7%). 
The individuals in both arms with a negative PPD test were followed up for a 
mean duration of 3 years. The overall conversion rate to positivity was 17.9 per 
100 person years of observation. The conversion rates in HIV positive and 
negative individuals were 14.4 and 18.3 per 100 person years of observation 
respectively(86). 
Further elucidating the complex pathophysiological mechanism behind this 
phenomenon will not only help in developing improved therapeutic strategies 
involving pharmacologic interventions, but also at improving the overall well-
being of the patient at completion of the prescribed course of therapy. This 
might further shorten the course of therapy and result in hastened 
microbiological clearance, thereby, improving outcome in Tuberculosis 
associated with immunodeficient states such as malnutrition and HIV-AIDS. 
So far, there have been attempts at studying the relationship between 
undernutrition and its effect on Tuberculosis as a disease and on its outcome. 
One approach is to look at cell mediated immunity in patients with Pulmonary 
Tuberculosis and Extra pulmonary Tuberculosis, and to see how the patient’s 
response to the disease is different (owing to changes in the CMI status). 
Attempts have also been made at studying the effectiveness of nutritional 
therapy on outcome of Tuberculosis.  In this study, we are using a novel 
approach. Our hypothesis is that nutritional improvement plays a pivotal role in 
determining clinical improvement. Patients who have nutritional improvement 
have an associated improvement in their immune response that helps the 
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individual contain the progression of the disease along with pharmacologic 
therapy.  We attempt to test this hypothesis by an observational study between 
nutritional recovery, PPD conversion and subjective improvement in sputum 
positive pulmonary Tuberculosis. 
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METHODOLOGY 
 
INSTITUTIONAL REVIEW BOARD: 
The institutional review board and ethics committee approved this study. The 
research funding was obtained from the fluid research grant of the institution. 
STUDY DESIGN 
This was a hospital based prospective observational study.  
STUDY SETTING 
The study was conducted in the departments of General Medicine and 
Community Health and Development (CHAD), Christian Medical College, 
Vellore.  
Patients with sputum positive pulmonary tuberculosis were identified. The 
diagnosis was based on Sputum AFB examination and TB-PCR (Xpert PCR) 
on sputum samples. Patients were recruited at the time of initiation of anti-
tuberculous therapy followed by detailed anthropometric and clinical 
assessment of nutritional status that included: 
1. Height  
2. Weight  
3. Body Mass Index  
4. Skin Fold Thickness – Triceps 
5. Mid Upper Arm Circumference  
6. Clinical assessment of macro and micronutrient deficiency 
a. Hair - Lack of luster, Depigmentation, Flag Sign 
b. Face – Nasolabial dys-sebacea 
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c. Eyes – Pallor, Bitot’s spots, Conjunctival / Corneal Xerosis 
d. Angular Stomatitis 
e. Tongue – Glossitis, Balding of tongue with atrophic papillae 
f. Parotid Enlargement 
g. Skin – Icthyosis, Petechiae, Perifollicular hemorrhages 
h. Koilonychia 
7. Hand Grip Strength Using a Dynamometer (Mechanical Dynamometer) 
a. Dominant Hand 
b. Non Dominant Hand 
Blood samples were collected at baseline and at end of therapy (continuation 
phase) for Haemoglobin and Albumin. All patients were given nutritional 
counselling at diagnosis. Patients will be administered 0.1ml of 5TU strength 
of PPD with Tween 80. This will be read at 48 hours from administration. The 
strength of the reaction will also be noted. Patients were reviewed at 2 months, 
and at the end of 6 months when baseline anthropometric and clinical 
parameters were repeated.  Patients were also administered HRQoL 
questionnaire (Health Related Quality of Life) at baseline, 2 months and 6 
months.  Chest X Ray was done at enrollment and at completion of therapy. 
Sputum AFB was performed at every encounter till clearance is documented.  
PPD was re-administered at 6 months and read after 48 hours. The principal 
investigator did data collection.  
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NUTRITIONAL COUNSELLING 
All patients diagnosed with sputum positive tuberculosis were requested to go 
to the Department of Dietetics were the following were performed:  
24-hour dietary recall 
Nutritional counseling  
Issue of weight appropriate diet sheet 
 
 
INCLUSION CRITERIA 
1. Adult patients (Age >16) presenting to Casualty, General Medicine 
OPD and CHAD OPD, diagnosed with Sputum Positive Tuberculosis 
2. Smear negative patients – but positive on TB PCR testing 
 
EXCLUSION CRITERIA 
1. History of Tuberculosis in the past, irrespective of the outcome 
2. Extra pulmonary Tuberculosis without Pulmonary Involvement 
3. Known XDR or MDR Tuberculosis 
4. HIV Positive Individuals 
5. Diabetics with BMI less than 18.5 
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WHO CLASSIFICATION OF CHRONIC ENERGY DEFICIENCY 
(BMI GRADES)(87) 
‘Normal    –   >18.5 BMI 
Grade I   –  17.0 – 18.5 
Grade II  –  16.0 – 16.9 
Grade III –  <16.0 ‘ 
 
QUANTIFICATION OF SPUTUM AFB (88)(89) 
‘No AFB in 100 fields examined                     -     Negative for AFB 
1 - 9 AFB in 100 fields  examined                -Exact Number 
0 - 99 AFB in 100 fields  examined             -          1+ 
1 - 10 AFB in fields examined                        -          2+ 
>10 AFB in fields examined                           -          3+’ 
 
 Adapted from Toman’s Tuberculosis – Case Detection, Treatment And 
Monitoring, WHO – Geneva , 2015.  
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PROCEDURE FOR HAND GRIP DYNAMOMETRY(90)(91) 
(Ref : Muscle Strength Procedures : NHANES – CDC 2011) 
This tests requires the use of a hand dynamometer to perform this test.  
The curved handle of the dynamometer mimics the pattern of the hand when 
making a fist.  
Attached to the hand grip is a monitor that shows the strength of the squeeze in 
kgs. 
Perform a series of sqeezes on the dynamometer with at least 30 seconds of rest 
between each squeeze to allow optimal recovery. 
Perform the test from a standing position with elbow bent at 90 degrees to the 
side of (not against) the subject’s body. 
Subject is asked to grab the dynamometer with a neutral grip, with thumb 
pointing up.  
Squeeze the dynamomter as hard as possible for 10 seconds.  
Record the highest value reached. 
Perform three trials for each hand. 
Document the best of three readings of the dominant and non dominant hand 
separately. 
Document if the patient is unable to perform the test along with the reason for 
the same.  
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PROCEDURE FOR ADMINISTRATION OF PPD(42) 
‘Skin testing for Tuberculosis utilizes a form of the diagnostic reagent 
Tuberculin. PPD ( Purified Protein Derivative) is administrated by intradermal 
injection by the Mantoux technique.  
Mantoux test uses a standard amount of PPD that is quantified and is 
reproducible.  
Injection will be administered intradermally using a tuberculin syringe with a 
26 gauge needle. 
Injection on the volar aspect of the left forearm is performed. This site is taken 
arbitrarily for uniformity and practiced as a part of standard procedure. 
Skin is first cleaned with alcohol swab.  
With the needle bevel upward, the skin is penetrated shallowly and a 6-10mm 
wheal is raised upon injection of 0.1ml. 
Test is read at 48 hours . A positive reaction usually includes both induration of 
the skin and surrounding erythema. The erythema has no diagnostic 
significance and should be ignored. 
Induration is measured precisely in mm in the transverse dimension 
Previous studies have reported inter-observer variability in PPD readings 
(minimal with no statistical significance). Faulty administration of PPD can 
also yield unreliable results. Hence, standard procedure will be followed in the 
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same and only primary investigator will do PPD administration and read the 
result.’ 
SAMPLE SIZE CALCULATION 
The required sample size to show a change (increase) in PPD reactivity of 
about 25% among undernourished individuals (BMI<18.5 kg/m2) who remain 
positive for TST at baseline and after 6 months as well, was found to be 128 
adults with 95% confidence limits and a precision of 7.5%. Incorporating 20% 
drop out, we propose to study 160 subjects.  
Reference for the above proportion: Delgado et al(85) 
Formula: 
 
 
Reference for the above formula(92)  
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Single Proportion - Absolute Precision  
Expected  Proportion 0.2 0.25 0.25 0.25 
Precision (%) 5 5 10 7.5 
Desired confidence level  (1- alpha) % 95 95 95 95 
Required sample size 246 288 72 128 
     
Survival analysis - Adjustment for lost to follow up  
Number of patients to be recruited in the 
study  128 128   
Proportion of lost to follow-up 0.1 0.2   
Required sample size for the study after 
adjustment  142 160   
 
Data entry was done into Epidata and then analyzed using SPSS software.  
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RESULTS 
This prospective cohort study was done from February 2017 through June 
2018. During this period 134 patients were recruited. Two patients refused to 
consent in the study. 46 patients completed the review at 6 months from 
recruitment. 17 out of 134 patients died during the 6 month follow up period. 
Thus, 134 were included in the baseline analysis and 46 patients in the final 
analysis (Figure 1). 
 
 
Figure 1: Strobe Diagram 
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BASELINE CHARACTERISTICS 
DEMOGRAPHIC CHARACTERISTICS (n=134) 
Gender Male    92 (68.7%) 
Female  42 (31.3%) 
Mean Age 44.816.4 
Type of Tuberculosis Pulmonary            117 (87.3%) 
Disseminated   17 (12.7%) 
Socioeconomic Class (SES) Upper               12 (9.0%) 
Upper Middle  53 (39.6%) 
Lower Middle 53 (39.6%) 
Upper Lower 15 (11.2%) 
Lower              1 (0.7%) 
History of Smoking 50 (37.3%) 
Comorbid Illness Diabetes           66(49.3%) 
Hypertension   21 (15.7%) 
Dyslipidemia   7 (5.2%) 
 
134 patients were recruited for the study after obtaining written informed 
consent. 92 subjects (68.7%) were men and 42 (31.3%) were women. The 
mean age of patients included in the study was 44.8 years. The majority of 
patients had only pulmonary tuberculosis (87.3%) and a minority of patient 
disseminated tuberculosis, with pulmonary involvement (17 patients). Three 
fourths of patients belonged to middle class as per the modified Kuppuswamy 
scale. The main co-morbid conditions were smoking and diabetes mellitus.  
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ANTHROPOMETRY AND NUTRITIONAL ASSESSMENT 
 
Mean Height (cm) 162.63  8.62 
Mean Weight (kg) 50.5  11.7 
Mean BMI (kg/m2) 19.02  3.89 
CED Grade Normal 68 (50.7%) 
CED I  19 (14.2%) 
CED II 13 (9.7%) 
CED III  34 (25.4%) 
Mean Triceps Skin Fold Thickness  (mm) 19.52  4.74 
Mean MUAC (cm) * 20.86  4.17 
Mean 24 hour dietary recall (kcal) 1794  452 
Hand Grip Dynamometry (kg) Dominant Hand 15.05  6.89 
Non Dominant 13.35  6.73 
Clinical Examination Pallor                        89 (66.4%) 
Icthyosis                    58 (43.3%) 
Parotid Enlargement  24 (17.9%) 
Angular Stomatitis  19 (14.2%) 
Glossitis                      67 (50.0%) 
Others                        28 (20.9%) 
Mean PPD Reading At Baseline (mm) 7.11  4.86 
HRQoL Score ** 
Mean Symptom Score 12.49  3.17 
Mean Social & Exercise Adaptation 
Score 
8.87  2.68  
Mean Total Score 21.36  5.85 
* MUAC – Mid Upper Arm Circumference 
** HRQoL – Health Related Quality of Life 
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A detailed anthropometric and nutritional assessment was performed at 
enrollment into the study. The mean height noted was 162.63 cm, mean weight 
was 50.5 kg and mean BMI was 19.02 kg/sq.m. Patients were categorized 
based on BMI into grades of chronic energy deficiency (CED). Nearly half the 
patients had chronic energy deficiency. 68 patients (50.7%) had normal BMI, 
and 19(14.2%), 13(9.7%), 34(25.4%) patients were noted to have CED grade I, 
II and III respectively. The mean 24 hour dietary recall was 1794 kcal which 
indicated poor calorie intake. Handgrip dynamometry (HGD) was performed 
which gave a mean reading of 15.05 kg in the dominant hand and 13.35 kg in 
the non-dominant hand. This suggests poor total muscle strength and 
nutritional status generally in the study population. However, it is important to 
note that HGD data needs to be interpreted with age and stature stratification 
and that a value in isolation is of little value. It does show that the measured 
mean HGD is low for any population. 
Clinical examination revealed the presence of micronutrient and macronutrient 
deficiencies in patients with pulmonary tuberculosis. Findings noted were 
pallor in 89 patients (66.4%), icthyosis in 58 (43.3%), parotid enlargement in 
24 (17.9%), angular stomatitis in 19 (14.2%), glossitis in 67 (50.0%) and other 
findings such as cheilitis, flag sign, nasal dyssebacia, and phrynoderma in 28 
patients (20.9%). 
Mean PPD reading at study enrollment was 7.11mm. Health related quality of 
life questionnaire was administered which looked at a symptom based score 
and second score based on social and exercise adaptation. Mean symptom 
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score was 12.49, mean social and exercise adaption score was 8.87 and mean 
total score at baseline was 10.68. This denotes poor quality of life (QOL) in 
patients at baseline assessment. A low score corresponds to poor QOL. The 
minimum attainable values for symptom, social and exercise adaptation, and 
total scores were 7, 5 and 12 respectively.  
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LABORATORY PARAMETERS 
 
Mean Hemoglobin (g/dL) 10.8  2.38 
Mean Albumin (g/dL) 3.17  3.17  
HIV Status  Positive            8 (6%) 
Negative           126 (94%) 
AFB Smear  1+                      45 (33.6%) 
2+                      27 (20.1%) 
3+                      30 (22.4%) 
Xpert Positive  32 (23.9%) 
 
 
Laboratory parameters measured in patients included hemoglobin and albumin 
at study enrolment. The mean hemoglobin was 10.8g/dL and the mean albumin 
was 3.17g/dL. Eight patients (6%) enrolled were seropositive for HIV. The 
basis of diagnosis of pulmonary tuberculosis was as follows. 102 patients were 
smear positive for AFB – 45(33.6%), 27(20.1%) and 30(22.4%) had 1+, 2+ and 
3+ smear positivity respectively.  Thirty-two patients (23.9%) were smear 
negative and were noted to have a positive CB-NAAT (Gene Xpert) positive 
test.  
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MEAN CALORIE INTAKE AND TYPE OF TUBERCULOSIS 
Type of Tuberculosis Mean Calorie Intake (24 hour recall) 
Pulmonary Tuberculosis 1809.76 kcal 
Disseminated Tuberculosis 1690.29 kcal 
 
The mean calorie intake in the patients with disseminated tuberculosis (1809.76 
kcal) was lower than for pulmonary tuberculosis (1690.29 kcal). However this 
difference was not statistical significant 
MEAN PPD READING AND TYPE OF TUBERCULOSIS 
Type of Tuberculosis Mean PPD Reading p value 
Pulmonary Tuberculosis (n – 117) 7.244.96 0.918(-2.37 – 2.63) 
Disseminated Tuberculosis (n – 17) 7.114.24 
 
MEAN BMI AND TYPE OF TUBERCULOSIS 
Type of Tuberculosis Mean BMI p value 
Pulmonary Tuberculosis (n – 117) 18.993.99 0.843(-2.20 – 1.80) 
Disseminated Tuberculosis (n – 17) 19.193.19 
 
MEAN WEIGHT AND TYPE OF TUBERCULOSIS 
Type of Tuberculosis Mean Weight p value 
Pulmonary Tuberculosis (n – 117) 50.3911.87 0.685(-7.34 – 4.84) 
Disseminated Tuberculosis (n – 17) 51.6411.94 
 
There was no significant difference with regard to the mean PPD reactivity, 
weight and BMI between patients who had pulmonary TB and disseminated 
TB. 
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OUTCOME – Including Data on Follow Up and Death  
OUTCOMES AT 6 MONTHS 
 
The outcome of patients included in the study was as follows. 46 patients 
completed follow up at 6 months from initiation of therapy. Outcome of this, 
all 46 were cured. There were no cases of treatment failure, defaulters in this 
group. 17 patients died during the 6-month period of follow up. 11 of these 
patients died during their initial admission during which the illness was 
diagnosed. 3 patients died post discharge during the intensive phase and 3 
patients died during the continuation phase.  71 patients were lost to follow up. 
Therefore the mortality rate was 12.7% and lost to followup 34.3%. 
 
 
 
 
 
Outcome – Status at 6 months from Recruitment 
Alive Total 46 
Cured  
Defaulted 
Failure  
Relapsed 
46 
0 
0 
0 
Died Total          17 
During IP 
In Hospital 
After Discharge 
During CP  
 
11 
3 
3 
Lost to Follow Up 71 
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FOLLOW UP AND GEOGRAPHIC REGIONS 
States  Completed Follow 
Up/ Died (%) 
Lost To Follow Up 
(%) 
Total 
Tamil Nadu 45 (71.4%) 48 (67.6%) 93 
Others 18 (28.5%) 23 (32.4%) 41 
Total 63 71 134 
 
Though patients recruited from Tamil Nadu was more, loss to follow up was 
similar in both groups. 
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COMPARISON OF PATIENTS WHO COMPLETED FOLLOW UP AT  
BASELINE AND AT 6 MONTHS (N = 46) 
 
PARAMETER BASELINE 6 MONTHS P value (95% 
CI) 
Mean Height (cm) 163.8 8.89 162.5  8.69 0.481(-2.32 – 4.94) 
Mean Weight (kg) 49.8411.52 56.33  11.54 0.008(1.72 – 11.26) 
Mean BMI (kg/m2) 18.533.93 20.95  3.34 0.002(0.90 – 3.93) 
CED Grade Normal 22(47.82%) 32 (69.65%)  
CED I 7(15.21%) 10 (21.74%)  
CED II 4(8.69%) 01 (2.17%)  
CED III 13(28.26%) 03 (6.52%)  
Mean Triceps Skin Fold 
Thickness  (mm) 
18.54.82 21.59  4.05 0.001(1.24 – 4.93) 
Hand Grip 
Dynamometry 
(kg) 
Dominant 
Hand 
14.426.81 20.11  5.52 0.001(3.12 – 8.25) 
Non 
Dominant 
12.416.38 18.70  6.00  0.001(3.72 – 8.85) 
Mean MUAC (cm) 20.234.33 21.80  3.92 0.071(-0.14 – 3.28) 
Mean PPD Reading (mm) 6.655.62 11.33  4.70 0.001(6.82 – 2.53) 
HRQoL Score 
Mean Symptom Score 12.353.29 20.15  0.98 0.001(7.10 – 9.11) 
Mean Social &Exercise 
Adaptation Score 
8.962.34 13.72  1.72  0.001(3.88 – 5.63) 
Mean Total Score 21.22 5.14 33.74  2.87 0.001(10.79 – 14.24) 
Mean Haemoglobin (g/dL) 10.232.04 12.75  1.51 0.001(1.77 – 3.26) 
Mean Albumin (g/dL) 3.020.79 4.12  0.44 0.001(0.83 – 1.36) 
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Detailed anthropometric and nutritional assessment was repeated at 6 months 
from initiation of therapy. The mean height noted was 162.5 cm, mean weight 
was 56.33 kg and mean BMI was 20.95 kg/sq.m. 32 patients (69.65%) had 
normal BMI, and 10(21.74%), 1(0.02%), 3(0.06%) patients were noted to have 
CED grade I, II and III respectively.  
Mean PPD reading at 6 months was 11.33 mm. Health related quality of life 
questionnaire was administered which looked at a symptom based score and 
second score based on social and exercise adaptation. Mean symptom score 
was 20.15, mean social and exercise adaption score was 13.72 and mean total 
score at baseline was 16.94. 
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Among the patients who were followed up to 6 months, there were significant 
increase: (a) in mean weight 49.84 kg to 56.33 kg (p=0.08), (b) BMI from 
18.53 to 20.95 (p=0.002), (c) triceps skin fold from 18.5 to 21.59 (p=0.001), 
(d) hand grip dynamometry in dominant hand 14.42 kg to 20.11 kg (p=0.001), 
(e) mean MUAC from 20.23 to 21.80 cm (p=0.07) (f) hemoglobin from 10.23 
to 12.75 g/dl (p=0.001) (g) albumin from 3.02 to 4.12 g/dl p=0.001). There 
were significant increase in the proportion of normal BMI, CED 1 grade and 
decline in CED grade 2 and 3. All these indicated improvement of nutritional 
status on treatment. There was significant improvement in PPD reactivity from 
mean PPD of 6.65 mm to 11.33 (p=0.001). 
There was also improvement in quality of life scores: mean symptom score 
from 12.35 to 20.15 and mean social and exercise adaptation score from 8.96 to 
13.72. 
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COMPARISON OF BASELINE PARAMETERS OF PATIENTS WHO 
COMPLETED FOLLOW AND PATIENTS WHO DIED 
 
Patients who died during the study period had a significantly lower PPD 
reactivity as baseline assessment  2.53( 3.02) mm, as compared to baseline 
PPD reactivity among patients who were alive at study completion6.65 ( 5.62) 
mm p=0.005(-6.99-1.24). 14 out of 17 patients who died had a PPD reading 
 5.0mm as compared to 16 out of 46 patients (82.35% and 34.78%). 
BASELINE PARAMETER Completed (n=46) Died (n=17) 
P value (95% CI) 
Mean Age 42.99  17.10 49.66  17.34 0.17(-3.07 – 16.41) 
Mean Weight (kg) 49.8411.52 50.50  9.36 0.83(-5.58 – 6.90) 
Mean BMI (kg/m2) 18.533.93 17.80  2.61 0.48(-2.79 – 1.33) 
CED Grade Normal 22(47.82%) 7 (41.12%)  
CED I 7(15.21%) 3 (17.64%)  
CED II 4(8.69%) 0 (0%)  
CED 
III 
13(28.26%) 7 (41.12%)  
Mean PPD Reading (mm) 6.65  5.62 2.53  3.02 0.005(-6.99 – -1.24) 
HRQoL Score 
Mean Symptom Score 12.043.29  11.81 2.78 0.79 (-2.02 – 1.56) 
Mean Social &Exercise 
Adaptation Score 
8.762.86 7.67  2.74  0.17 (-2.69 – 0.51) 
Mean Total Score 20.803.48 18.66  4.37 0.04 (-4.25 – -0.02) 
Mean Haemoglobin (g/dL) 10.232.04 9.38  1.83 0.14(-1.97 – 0.27) 
Mean Albumin (g/dL) 3.020.79 2.90  0.80 0.59(-0.56 – 0.32) 
PPD Reading 
(mm) 
 5.0 16(34.78%) 14(82.35%)  
5.1 – 
10.0 
16(34.78%) 2(11.76%)  
 10.1 14(30.43%) 1(5.88%)  
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BASELINE PARAMETERS OF PATIENTS WHO COMPLETED 
FOLLOW AND PATIENTS WHO WERE LOST TO FOLLOW UP  
There was a high rate of lost to follow-up in this study. Hence we compared the group 
that completed follow up to those who were lost to follow-up, to determine if there 
were differences in the two groups which could have influenced the results of the 
follow-up study. We found that there was no difference in the two groups with regard 
to nutritional status, PPD reactivity and quality of life scores. 
PARAMETER AT BASELINE Completed 
Follow Up (n=46) 
Lost to Follow 
Up (n = 71) 
Mean Height (cm) 163.8 8.89 162.62  8.62 
Mean Weight (kg) 49.8411.52 50.40  11.83 
Mean BMI (kg/m2) 18.533.93 18.99  4.09 
CED Grade Normal 22(47.82%) 42 (59.15%) 
CED I 7(15.21%) 6 (8.45%) 
CED II 4(8.69%) 5 (7.04%) 
CED III 13(28.26%) 18 (25.32%) 
Mean Triceps Skin Fold Thickness  
(mm) 
18.54.82 19.48  5.05 
Hand Grip 
Dynamometry (kg) 
Dominant Hand 14.426.81 14.66  6.54 
Non Dominant 12.416.38 13.11  6.32  
Mean MUAC (cm) 20.234.33 20.90  4.34 
Mean PPD Reading (mm) 6.655.62 7.02  5.04 
HRQoL Score 
Mean Symptom Score 12.043.29 12.56  3.27 
Mean Social &Exercise Adaptation 
Score 
8.762.86 8.81  2.85  
Mean Total Score 20.803.48 21.38  3.59 
Mean Haemoglobin (g/dL) 10.232.04 10.57  2.47 
Mean Albumin (g/dL) 3.020.79 3.15  1.01 
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CLINICAL DATA OF PATIENTS WHO DIED DURING THE STUDY 
PERIOD 
No Age Cause  Day (From 
diagnosis) 
Significant 
comorbidities 
1 22 Aspiration Pneumonia 29 TBM – MRC III 
Coma Vigil 
DVT 
2 56 Diabetic Ketoacidosis with 
septic shock 
4 Klebsiella Pneumonia 
3 52 Acute Liver Failure – ATT 
DILI, Refractory 
Hypotension 
18 Renal Allograft 
recipient, Oliguric 
Renal Failure 
4 29 Type 1 DM with DKA, 
Hospital Acquired 
Pneumonia 
NA (Died in 
another 
centre) 
DILI 
5 49 HHS, Candidemia 20 Type 2 DM with poor 
glycemic control 
6 71 Acute Coronary Syndrome 26 Aspiration 
Pneumonia, TBM – 
MRC III 
7 59 DKA, Septic Shock 3 Invasive 
Rhinocerebral 
Mucormycosis 
8 68 Acute Coronary Syndrome 4 Rheumatoid Arthritis 
9 42 Type 1 Respiratory Failure, 
ARDS 
6 HIV Clinical Stage IV 
10 69 GNB Sepsis 20 Recent ACS 
11 65 Septic Shock with oliguric 
renal failure 
7 T2DM 
12 56 NA NA Non Hodgkin 
Lymphoma 
13 54 Candidemia with Septic 
Shock 
24 T2DM 
14 46 HHS with septic Shock 3 ARDS, T2DM 
15 16 Type 1 Respiratory Failure 7 Tetrology of Fallot - 
Uncorrected 
16 64 NA NA Hilar 
Cholangiocarcinoma 
17 49 NA NA T2DM 
Patients who died during the study period had significant co-morbid illnesses 
and it is clear that the severity of these illnesses might contributed more to 
death than the severity of tuberculosis.  
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TREATMENT RELATED COMPLICATIONS 
 
Event Frequency in PPD +  Frequency in PPD - 
DILI 1 10 9 
Dyselectrolytemia 16 14 
Venous Thrombosis 2 2 4 
Acute Coronary Syndrome 0 3 
Type I Respiratory Requiring  
Ventilation 3 
2 7 
GPC Bacteremia 4 1 1 
GNB Bacteremia 5 1 3 
Secondary Pneumonia 4 8 
Readmission 3 2 
Ethambutol Optic Neuritis 0 1 
Drug Rash 1 1 
DKA / HHS 6 11 4 
Candidemia  0 2 
Total 51 59 
1 – Drug Induced Liver Injury, 2 – DVT, Pulmonary Embolism, Cortical Venous Thrombosis, 3 – Includes cases that required 
invasive and non invasive ventilation, 4 – Gram Positive Cocci, 5 – Gram Negative Bacilli,  6 – Diabetic Ketoacidosis, 
Hyperglycemic hyperosmolar syndrome  
 
There were no significant difference in the occurrence of complications 
between the patients whose baseline PPD reading was >5mm and 5mm.  
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PPD REACTIVITY AT BASELINE AND ON TREATMENT 
DISTRIBUTION OF PPD AT BASELINE 
PPD Reading (mm) Frequency, n – 134 (%) 
0.0 – 5.0 58 (43.3%) 
5.1 – 10.0 37 (27.6%) 
> 10.0 39 (29.1%) 
 
43.3% of patients had anergy and 29.1% of patients were strongly PPD 
positive. 
 
DISTRIBUTION OF PPD READING AT 6 MONTHS 
 
PPD Reading (mm) Frequency, n – 46 (%) 
0.0 – 5.0 10 (21.7%) 
5.1 – 10.0 8 (17.4%) 
> 10.0 28 (60.2%) 
 
The rates of anergy declined to 21.7% at followup and the majority of patients 
were strongly PPD reactive (60.2%). 
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CHANGE IN PPD FROM BASELINE TO  PPD AT 6 MONTHS (n=46) 
68.5% of anergic patients becames PPD positive. 56.3% of patients with baseline PPD 
between 5.1-10 mm became strongly PPD positive. All the patients with strongly PPD 
positivity (> 10 mm) at baseline continued to be strongly PPD positive at followup.  
BASELINE PPD (mm) was 
1. 0-5 – 16(n) 
Out of this at 6 months 
i.6 persisted to be anergic – 0-5mm – n=6(37.5%) 
ii.5 had a reading from 5-10mm –n=5 (31.3%) 
iii.5 had a positive PPD reading (>10mm) – n=5 (31.3%) 
iv.5+6 had a shift in PPD class (68.5%) 
 
2. 5.1-10 – 16(n) 
Out of this at 6 months 
i.4 had shift class to become anergic – n=4 (25%) 
ii.3 persisted to have a reading of 5-10mm – n=3(18.8%) 
iii.9 had a positive PPD reading (>10mm) – n=9 (56.3%) 
iv.4 had a negative PPD class shift 
v.9 had a positive PPD class shift 
 
 
3. >10 – 16(n) 
Out of this at 6 months 
i.0 had shift class to become anergic – n=0 
ii.0 had shift class to become 5-10mm – n=0 
iii.14 had a positive PPD reading (>10mm) – n=14 (100%) 
iv.0 had a negative PPD class shift 
v.0 had a positive PPD class shift 
 
 67 
PPD CONVERSION IN PATIENTS WHO WERE ANERGIC AT 
BASELINE (PPD CONVERSION RATE – n = 46) 
BMI  PPD  5 At 
Baseline 
PPD> 5 At 6 
Months 
% Conversion 
Normal 6 4 66.66% 
CED I 4 4 100% 
CED II 2 1 50% 
CED III 6 3 50% 
Total 18 12 66.66% 
 
Of 18 patients who were anergic at baseline, 12 patients had PPD 
conversion. Among the patients who were anergic at baseline, all the 
patients in CED I converted and 50% in CED II and III categories and 
66.66% of normal BMI. This table shows the patients who were anergic at 
baseline and PPD conversion in this subset at 6 months with completion of 
therapy.  
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ANERGY TO PPD 
ASSOCIATION BETWEEN PPD ANERGY AND BMI AT BASELINE 
 
 PPD  5.0mm 
(%) 
PPD > 5.1mm 
(%)  
Total 
Normal BMI 20 (34.48) 48 (63.15) 68 
CED (I, II, III) 38 (65.51) 28 (36.84) 66 
Total 58  76 134 
 
 
The proportion of patients who were anergic in CED was greater than in the 
normal BMI group with a relative risk of 1.957. 
RR Of Anergy with CED = Incidence among exposed/Incidence among 
unexposed 
                                              = (38/66) / (20/68) 
        = 0.5757/0.2941 = 1.957 
 
The relative risk of a patient with Pulmonary TB being anergic to PPD 
with chronic energy deficiency was 1.957 compared to a patient with 
normal BMI.  
 
95% Confidence Interval: 1.28 – 2.98 
P value: 0.0018 
Number needed to harm: 3.551 
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ASSOCIATION BETWEEN PPD ANERGY AND RECURRENCE OF 
TUBERCULOSIS 
 
 PPD  5.0mm (%) PPD > 5.1mm 
(%) 
 
PAST H/O TB + 8   (13.79) 4     (5.26) 12 
PAST H/O TB - 50 (86.20) 72 (94.73) 122 
Total 58 76 134 
 
Past history of tuberculosis was documented in patients at recruitment. 12 
patients gave history of Tuberculosis (treated) in the past. 8 of the 12 patients 
were noted to be anergic at baseline. 
RR Of Anergy with Past history of Tuberculosis = Incidence among 
exposed/Incidence among unexposed 
                                              = (8/12) / (50/122) 
        = 1.62 
 
The relative risk of a patient being anergic to PPD with past history of 
tuberculosis is 1.62 compared to a patient with negative history for the 
same.  
95% Confidence Interval: 1.04 – 2.56 
P value: 0.0354 
Number needed to harm: 3.894 
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ASSOCIATION BETWEEN PPD ANERGY AT BASELINE AND 
DEATH (N=63) 
 
 Dead (%) Alive (%)  
PPD  5.0mm 14 (82.35) 16 (34.78) 30 
PPD > 5.1mm 3   (17.64) 30 (65.21) 33 
Total 17 46 63 
 
 
RR Of Death with Anergy at Baseline = Incidence among exposed/Incidence 
among unexposed 
                                              = (14/30) / (3/33) 
        =  5.133 
 
The relative risk of a patient who died during the study period of having anergy 
to PPD at baseline was 5.133 compared to a patient who was alive at 6 months.  
 
95% Confidence Interval: 1.63 to 16.12 
P value: 0.0051 
Number needed to harm: 2.661 
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BASELINE PARAMETERS OF PATIENTS WHO REMAINED PPD 
ANERGIC AT 6 MONTHS AND PATIENTS WHO HAD PPD 
CONVERSION 
 
PARAMETER AT BASELINE Anergic At 6 
months (n=6) 
PPD Converted 
at 6m (n=12) 
T test (95 % CI) 
Mean Height (cm) 162.9010.25 163.167.83 0.82(-10.17 – 8.17) 
Mean Weight (kg) 45.9013.16 49.7510.94 0.52(-16.22 – 8.52) 
Mean BMI (kg/m2) 17.043.29 18.562.90 0.33(-4.72 – 1.69) 
CED Grade Normal 2(33.33%) 4(33.33%) 
 
CED I 0(0%) 4(33.33%) 
 
CED II 1(16.67%) 1(0.08%) 
 
CED III 3(50%) 3(25%) 
 
HGD(kg) RIGHT 13.508.18 13.757.11 0.95(-8.15 – 7.65) 
LEFT  12.008.23 12.916.89 0.81(-8.68 – 6.86) 
Mean MUAC (cm) 18.603.62 19.912.74 0.40(-4.53 – 1.91) 
Mean PPD Reading (mm) 1.831.60 3.002.00 0.23(-3.16 – 0.83) 
HRQoL Score 
Mean Symptom Score 10.003.03 12.912.35 0.04(0.17 – 5.64 ) 
Mean Social &Exercise Adaptation 
Score 
7.000.89 9.002.25 0.05(0.04 – 4.05) 
Mean Total Score 173.52 21.924.35 0.02(0.57 – 9.27) 
Mean Haemoglobin (g/dL) 11.383.13 10.722.53 0.43(-1.78 – 4.01) 
Mean Albumin (g/dL) 3.130.42  3.230.71 0.76(-0.77 – 0.57) 
Mean Age 37.3312.40 42.757.56 0.26(-15.32 – 4.49) 
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Among the patients who did not convert, the mean baseline PPD was 1.83 
mm compared to 3 mm in those who converted. Among the the patients 
who did not convert, the mean symptom score, social and exercise 
adaptation score and mean total score was significantly lower compared to 
those who converted.  
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CHANGE IN NUTRITIONAL STATUS (BMI AND WEIGHT) 
MEAN CHANGE IN WEIGHT AND BMI 
BMI Category – 
Baseline 
Mean Weight  Gain (kg) P value (95% CI) 
Compared with Normal BMI 
Normal  (n – 22) 4.86  3.41  
CED I    (n – 9) 6.33  4.18 0.32 (-4.41 – 1.47) 
CED II   (n – 6) 5.66  2.16 0.59 (-3.83 – 2.23) 
CED III  (n – 9) 6.11  3.33 0.36 (-3.99 – 1.49) 
Total  (n – 46) 5.50  3.31  
 
All patients with pulmonary TB had increase in body weight on treatment of a 
mean of 5.5 kg. The increase in weight in CED categories was 6.33 kg in CED I, 
5.66 kg in CED II and 6.11 kg in CED III compared to 4.86 kg in normal BMI. 
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BASELINE PARAMETERS OF PATIENTS WHO HAD SIGNIFICANT 
WEIGHT GAIN COMPARED WITH THOSE WHO DID NOT AT 
SIX MONTHS 
 
 
There were no significant difference between the baseline characteristics 
of patients who had a significant weight gain of 4 kg and those who did 
PARAMETER AT BASELINE No weight gain 
(n=14) 
Significant 
weight gain 
(n=32) 
T test (95 % 
CI) 
Mean Height (cm) 164.218.34 162.949.14 0.65(-4.48 – 7.02) 
Mean Weight (kg) 55.5714.84 48.839.89 0.07(-0.73 – 
14.21) 
Mean BMI (kg/m2) 20.374.17 18.332.99 0.06(-0.14 – 4.22) 
CED Grade Normal 8(57.14%) 12(37.50%)  
CED I 4(28.57%) 6(18.75%)  
CED II 0(0%) 5(15.62%)  
CED III 2(14.28%) 9(28.12%)  
Mean Age 41.2117.10 43.7714.15 0.59(-12.29 – 
7.17) 
Hand Grip 
Dynamometry (kg) 
Right 13.846.17 15.567.63 0.46(-6.39 – 2.94) 
Left 13.468.00 13.827.29 0.88(-5.20 – 4.48) 
Mean PPD Reading (mm) 5.645.59 7.834.13 0.14(-5.16 – 0.78) 
HRQoL Score 
Score 1 12.423.00 12.423.27 1.00(-2.06 – 2.06) 
Score 2 8.641.98 9.242.64 0.45(-2.19 – 0.99) 
Mean Total Score 21.074.53 21.665.47 0.72(-3.95 – 2.77) 
Mean Haemoglobin (g/dL) 10.991.79 11.272.49 0.70(-1.76 – 1.20) 
Mean Albumin (g/dL) 3.120.34 3.30 0.76 0.40(-0.60 – 0.24) 
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not. 57.14% of patients who had failure of weight gain had a normal BMI 
at baseline.  
Patients who did not have significant weight gain at 6 months were also noted 
to have a higher baseline weight and BMI as compared to patients who had 
significant weight gain. The lowest mean weight gain among patients who 
completed therapy across BMI categories was 4.86kg. Hence, 4kg was 
considered minimum significant weight gain. 
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QUALITY OF LIFE 
CHANGE IN MEAN QUALITY OF LIFE SCORE ON TREATMENT 
ACCORDING TO BASELINE BMI CATEGORIES 
Baseline BMI Mean Score at 
Baseline 
Mean Score at 6 
Months  
t-test p,  
95% CI  
Normal    (n – 22) 22.154.99 33.652.81 <0.001(8.90 – 14.09) 
CED I      (n – 09) 22.305.49 34.302.31 <0.001(8.04 – 15.95) 
CED II     (n – 06) 18.833.97 32.164.70 <0.001(7.73 – 18.93) 
CED III   (n – 09) 18.804.56 34.002.05 <0.001(11.87 – 18.52) 
Total        (n – 46) 21.225.14 33.742.87 <0.001(10.79 – 14.24) 
 
There was a significant increase in Mean HRQoL on treatment in all 
patients and in each of the BMI categories. 
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IMPROVEMENT IN HEALTH RELATED QUALITY OF LIFE (n=46) 
 
 SCORES (Mean  SD)  
Paired t Test 0 weeks 6months Avg. Gain 
Score 1  12.35  2.99 20.15  0.98 7.80 0.01 
Score 2 8.96  2.34 13.72  1.72 4.76 0.03 
Total Score 21.22  5.14 33.74  2.87  12.52 <0.001 
 
There was significant increase in total health related quality of life score 
and score 1 and 2 between baseline and at completion of treatment.  
 
 
 
 
 
Score 1 – Symptoms Score, Score 2- Social and Exercise Adaptation Score 
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BASELINE CHARACTERISTICS OF PATIENTS WHO HAD A LOW 
HQROL SCORE AT BASELINE (HRQOL < 18) 
 
BASELINE PARAMETERS OF PATIENTS WHO DID NOT 
IMPROVEMENT IN  HRQOL SCORE AT BASELINE 
COMPARED WITH SUBSET OF THESE PATIENTS WHO HAD 
SIGNIFICANT GAIN IN SCORE 
The lowest possible HRQOL score was 12 and the average gain in total score 
at 6 months was 12. Hence half this value (6) was taken as minimum 
meaningful gain in score. However, such a comparison was not possible as all 
patients with low HRQOL score at baseline had a significant gain in score at 6 
months. 
PARAMETER AT BASELINE Score < 18 (n=13) 
Mean Height (cm) 162.768.40 
Mean Weight (kg) 44.539.89 
Mean BMI (kg/m2) 16.682.76 
CED Grade Normal 3(23.07%) 
CED I 2(15.38%) 
CED II 1(7.69%) 
CED III 7(53.48%) 
Mean Triceps Skin Fold Thickness  (mm) 17.303.27 
Hand Grip 
Dynamometry (kg) 
Dominant Hand 10.768.12 
Non Dominant 9.617.76 
Mean MUAC (cm) 18.463.28 
Mean PPD Reading (mm) 5.154.18 
Mean Symptom Score 9.154.18 
Mean Social &Exercise Adaptation Score 6.611.04 
Mean Total Score 15.761.36 
Mean Haemoglobin (g/dL) 10.763.25 
Mean Albumin (g/dL) 3.120.74 
Mean Age 37.3814.22 
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SCORE AT BASELINE AND 6 MONTHS IN PATIENTS WITH 
INITIAL SCORE OF < 18 
Patient  Baseline Score Score at 6 months 
Patient 1  16 34 
Patient 2 16 33 
Patient 3 16 35 
Patient 4 16 36 
Patient 5 15 30 
Patient 6 13 21 
Patient 7 17 35 
Patient 8 13 35 
Patient 9 17 36 
Patient 10 16 33 
Patient 11 17 33 
Patient 12 17 36 
Patient 13 16 32 
 
13 patients were identified at baseline with a low QOL score. The mean score 
at baseline and 6 months in this subset was 15.771.36 and 33.124.02 
respectively. The mean increase in this group was 17.35. The mean increase in 
the 46 patients who completed follow up was 12.52. None of the patients who 
had a low score at baseline failed to have significant improvement in the QOL 
score.  
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BMI AND PPD COMPARISON 
DISTRIBUTION OF PPD AS PER BASELINE BMI CATEGORIES 
 
PPD Baseline(mm) CED Grade  
Normal CED I CED II CED III 
PPD 0 – 5.0 20 (29.4%) 9 (47.4%) 5 (38.5%) 24 (70.6%) 
5.1 - 10 17 (25.0%) 6 (31.6%) 6 (46.2%) 8 (23.5%) 
>10 31 (45.6%) 4 (21.1%) 2 (15.4%) 2 (5.9%) 
Total 68 19 13 34 
50.7% 14.2% 9.7% 25.4% 
 
The majority of patients with pulmonary TB in CED III (70.6%) were anergic 
compared to, 38.5% in CED II and 47.4% in CED I and  29.4% in patients 
normal BMI. Only 5.9% of CED III were strongly PPD positive compared 
to 9.7% in CED II, 21.1% in CED 1 and 45.6% in normal BMI. 
 
MEAN CHANGE IN WEIGHT AND BASELINE PPD RESPONSE 
PPD Reading at Baseline (mm) Mean Gain in Weight (kg) 
0.0 – 5.0 4.31  3.96 
5.1 – 10.0 6.37  4.16 
>10.0 5.88  2.63 
Total  (n-46) 5.50  3.33 
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PPD READING COMPARED WITH BMI AT 0 AND 6 MONTHS 
 
 Frequency Mean (mm) Std. Deviation 
PPD Reading 
Baseline 
Normal 68 9.13 5.03 
CED I 19 6.00 4.15 
CED II 13 6.23 4.38 
CED III 34 4.03 2.84 
Total 134 7.11 4.58 
PPD Reading      
6 Months 
Normal  22 12.41 4.56 
CED I 9 12.11 4.37 
CED II 6 12.50 3.39 
CED III 9 7.11 4.31 
Total 46 11.33 4.70 
 
The mean increase in PPD reactivity in all patients with pulmonary TB was 
4.23 mm. There was a statistically significant increase in PPD in all CEd 1 and 
2 subgroups compared to normal BMI group. The mean increase in PPD 
reactivity according to BMI categories was: CED I -6.11 mm, CED II - 6.27 
mm and CED III - 3.08 mm and in normal BMI-3.28 mm. The maximum 
increase was in CED I and II categories. 
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COMPARISON OF MEAN PPD CHANGE IN CED GRADES AS 
COMPARED TO NORMAL BMI 
Baseline BMI Mean PPD Change (mm) P value (95 % CI) 
Compared with Normal BMI 
Normal    (n – 22) 3.281.49  
CED I      (n – 09) 6.112.13 0.02 (-3.07 – -0.34) 
CED II     (n – 06) 6.271.98 0.001(-4.88 – -1.85) 
CED III   (n – 09) 3.081.46 0.04 (0.09 – 4.28)  
Total        (n – 46) 4.680.96  
 
CHANGE IN PPD REACTIVITY ON TREATMENT 
ACCORDING TO BASELINE BMI CATEGORIES 
Baseline BMI Mean PPD at Baseline 
(mm) 
Mean PPD at 6 Months 
(mm) 
Paired t-test p,  
95% CI  
Normal    (n – 22) 8.615.07 12.414.56 0.01 (0.79 – 6.80) 
CED I      (n – 09) 6.604.85 12.114.37 0.01 (1.02 – 9.99) 
CED II     (n – 06) 5.333.50 12.503.39 0.005(2.73 – 11.60) 
CED III   (n – 09) 4.601.64 07.114.31 0.10 (-5.80 – 5.60) 
Total        (n – 46) 6.824.53 11.334.70 <0.001 (2.08 – 6.93) 
 
There was significant increase in PPD reactivity in all patients and CED 
categories except in CED III category. 
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BMI AND QUALITY OF LIFE – COMPARISON 
The mean quality of life score (total) was 22.15 and 18.80 in patients with 
normal BMI and CED grade III at baseline respectively.  
PPD AND QUALITY OF LIFE - COMPARISON 
Among the 46 patients who completed follow up, the mean quality of life score 
was 23.22 and 17.90 in patients with a positive and negative response to PPD 
at baseline. 
13 patients were identified at baseline with a low QOL score. The mean score 
at baseline and 6 months in this subset was 15.771.36 and 33.124.02 
respectively. The mean increase in this group was 17.35. The mean increase in 
the 46 patients who completed follow up was 12.52. None of the patients who 
had a low score at baseline failed to have significant improvement in the QOL 
score. 
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INTER-RELATIONSHIP OF WEIGHT, PPD REACTIVITY 
AND QUALITY OF LIFE (AT 6 MONTHS) 
CHANGE IN WEIGHT, QOL AND PPD REACTIVITY TREATMENT 
ACCORDING TO BASELINE BMI CATEGORIES 
Baseline BMI Mean Weight Gain 
(kg), SE 
Mean QOL 
Change, SE 
Mean PPD Change 
(mm), SE 
Normal    (n – 20) 4.86, 0.72 11.50, 1.28 3.80, 1.49 
CED I      (n – 10) 6.33, 1.39 12.00, 1.88 5.51, 2.13 
CED II     (n – 06) 5.66, 0.88 13.33, 2.51 7.17, 1.98 
CED III   (n – 10) 6.11, 1.11 15.20, 1.58 2.51, 1.46 
Total        (n – 46) 5.50, 0.49 12.52, 0.87 4.68, 0.96 
 
The table shows that there is increase in mean weight, QOL and PPD 
change in all patients and in each of the BMI categories. The increase in 
body weight and QOL was maximum in the CED categories and PPD in 
the CED I and II categories. 
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PATIENTS WITH PPD ANERGY AND NO WEIGHT GAIN AT 6 
MONTHS 
Patient  PPD Anergy No Weight Gain 
Patient 1  Yes Yes 
Patient 2 Yes Yes 
Patient 3 Yes Yes 
Patient 4 Yes No 
Patient 5 Yes Yes 
Patient 6 Yes No 
Patient 7 No Yes 
Patient 8 No Yes 
Patient 9 No Yes 
Patient 10 No Yes 
Patient 11 No Yes 
Patient 12 No Yes 
Patient 13 No Yes 
Patient 14 No Yes 
Patient 15 No Yes 
Patient 16 No Yes 
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All the anergic patients at baseline who converted on treatment had 
significant weight gain. Four out of the 6 patients who remained anergic at 
completion of treatment had failure to gain weight. 
 
 
 
 
ASSOCIATION BETWEEN PERSISTENT PPD ANERGY (OR 
NEGATIVE CLASS SHIFT TO NEW ONSET ANERGY) AND 
FAILURE TO GAIN WEIGHT AT 6 MONTHS 
 
 PPD  5.0mm PPD > 5.1mm  
WEIGHT GAIN + 2 30 32 
NO WEIGHT 
GAIN 
8 6 14 
Total 10 36 46 
 
There was a significant association between persistent anergy or negative class 
shift with failure to gain weight at 6 months with a relative risk of 9.14. 
RR Of  Persistent Anergy  or Negative Class Shift with Failure to gain weight 
at 6 months = Incidence among exposed/Incidence among unexposed 
                                              = (8/14) / (2/32) = 9.14 
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The relative risk of a patient being persistently anergic to PPD or have a 
negative class shift to new onset anergy with failure to gain weight at 6 months 
was 9.14 compared to a patient who had significant weight gain.  
95% Confidence Interval: 2.22 – 37.69 
P value: 0.0022 
Number needed to harm: 1.965 
Mean QoL increase in patients who remained anergic or had a negative class 
shift at 6 months was 16.10  1.79. (Mean increase was 12.52  1.89 in 46 
patients who completed follow up). 
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DISCUSSION 
This prospective observational cohort study was designed to gauge the 
relationship between tuberculin reactivity and undernutrition in patients newly 
diagnosed with sputum positive pulmonary tuberculosis, the rate of tuberculin 
conversion in tuberculin negative patients on treatment, weight gain in 
underweight patients, and to correlate weight gain, tuberculin conversion and 
improvement in quality of life.   
This was a hospital-based study and majority of the subjects recruited were in-
patients admitted to the hospital (65%). The remaining patients were recruited 
from the outpatient clinic and CHAD (Community Health and Development) 
hospital. The mortality noted at 6 months was 17/63 subjects (26.98%). This is 
higher than the expected mortality rate in patients with sputum positive 
pulmonary tuberculosis. The fact that the majority of patients recruited into the 
study were admitted in-patients must be taken into consideration while 
interpreting this data. 11 out of 17 patients died during the index admission 
when tuberculosis was diagnosed.  
PPD (Purified Protein Derivative) reactivity has been used as a tool for 
diagnosis of latent tuberculosis in adults and as a pointer of active infection in 
children. Our approach was different. PPD was not used as a diagnostic tool for 
detection of tuberculosis. Rather, tuberculin reactivity was used as an indicator 
of the integrity of the cell mediated immune system of a patient diagnosed with 
sputum positive pulmonary tuberculosis.  
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Our hypothesis was that there exists an inter relationship between 
undernutrition, cell mediated immunity, clinical improvement and quality of 
life. Microbiological cure in isolation need not represent overall well rounded 
recovery in a patient at the end of therapy. This would mean that patients who 
are declared ‘cured’ microbiologically do not belong to a homogenous class. 
Rather, there is heterogeneity in the class with regard to weight gain and 
apparent well-being. Patients who do not gain weight and have persistent 
anergy could represent a subset that has not reached their pre-morbid state of 
wellness. This could also represent a class that is at high risk of developing 
reactivation or re-infection with tuberculosis.  
 
 
 
 
Should the hypothesis be true, we expect a relationship between BMI and PPD, 
and BMI and quality of life at baseline and at completion of therapy.  
 
 
Nutrition
Quality of 
life
Immunity
 90 
Baseline: 
Out of the 134 patients recruited for the study, 43.3%(n-58) had a PPD 
reading 5mm and 70.9% (n-95) had a PPD reading 10mm at baseline 
evaluation. 7.46%(n-10) patients had no detectable reaction to PPD. Baseline 
PPD anergy was much higher (43.3% vs 33.0%) than reported by Delgado et al 
in a study done in Cambodia among sputum positive pulmonary 
Tuberculosis(85). 
The majority of patients with CED III remained anergic compared to the 
majority of patients with normal BMI who were PPD reactive. To determine 
this association, PPD response was compared in patients with normal BMI and 
patients with CED (I+II+III). The relative risk of anergy with CED at baseline 
was 1.957(95% CI 1.28 – 2.98), p value: 0.0018. This establishes the fact that 
poor nutritional status (determined by BMI and Chronic energy deficiency 
grades) reliably predicts anergy to PPD.  
The mean quality of life score (total) was 22.15 and 18.80 in patients with 
normal BMI and CED grade III at baseline respectively. Among the 46 patients 
who completed follow up, the mean quality of life score was 23.22 and 17.90 
in patients with a positive and negative response to PPD at baseline. As 
expected and in keeping with our hypothesis, patients with anergy and 
CED at baseline also had a low quality of life score. 
6 Months:  
 91 
The mean PPD reading among the 46 patients who completed follow up was 
6.655.62mm at baseline and 11.334.70mm at 6 months. The mean change in 
PPD was 4.68mm with standard error of 0.96. Out of the 46 patients who 
completed follow up at 6 months, 16 (34.76%) were anergic at baseline and 6 
(13.04%) had persistent anergy. The corresponding mean weight gain and 
mean change in quality of life score were 5.50kg (SE – 0.49) and 12.52(SE – 
0.87) respectively. It is evident that there is an overall gross improvement 
in weight, quality of life and PPD reactivity at 6 months as compared to 
baseline parameters.  
Corollary to this hypothesis, patients who failed to attain tuberculin conversion 
(negative to positive) must also have a failure to have significant weight gain 
during the study period. Treatment exposure was comparable in both groups. 
Patients who were persistently anergic and failed to gain weight were looked at 
separately. The relative risk of a patient being persistently anergic to PPD 
or have a negative class shift to new onset anergy with failure to gain 
weight at 6 months was 9.14 compared to a patient who had significant 
weight gain (95% CI 2.22 – 37.69), p value: 0.0022. All patients who 
completed follow up had significant improvement in quality of life score. As 
mentioned above, a subset of patients remained anergic and failed to gain 
weight.  
13 patients were identified at baseline with a low QOL score. The mean score 
at baseline and 6 months in this subset was 15.771.36 and 33.124.02 
respectively. The mean increase in this group was 17.35. The mean increase in 
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the 46 patients who completed follow up was 12.52. None of the patients who 
had a low score at baseline failed to have significant improvement in the QOL 
score. 
Sputum positive pulmonary tuberculosis (active infection) is a condition where 
a strong response to intradermal instillation of PPD should be elicited. At the 
end of the study, we have identified a subset of patients who, despite active 
infection and adequate treatment, with microbiological cure, continue to elicit 
no response to PPD administration. Further characterization of these patients 
with T cell population subset analysis and measurement of established effector 
cytokines such as IL-2, IL-10 and IFN- should help us understand the 
underlying mechanism behind anergy at the cellular and cytokine level(15).  
Past history of tuberculosis (treated) was documented at the time of 
recruitment. 12 patients gave history of having been treated for tuberculosis in 
the past. 8 out of the 12 had a negative PPD reading at baseline. The relative 
risk of anergy with past history of tuberculosis was 1.62(95 % CI 1.03 – 
2.56, p: 0.035).From the above data, it is apparent that this subset of 
patients is at a higher risk of recurrence of the disease (reactivation or re-
infection) at a later point of time. However, in concluding the same, we 
assume that they were more likely to have been anergic at the time of their 
initial infection, had they been tested.  
17 patients died during the study period. 14 out the 17 had a PPD reading  
5mm at baseline. The relative risk of death with anergy to PPD at baseline 
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was 5.133 compared to a patient with a PPD response more than 5mm (CI 
1.63 – 16.12, p:0051). Patients who died during the study period were more 
likely to be anergic. However, the causal association remains unclear. 
This cohort of patients has to be followed up for sufficiently long periods (>10 
years) to determine whether the persistence of anergy to PPD in them puts 
them at a higher risk of developing re-infection or reactivation of tuberculosis. 
Available data suggests that anergy to PPD has a profound impact on mortality 
and persistent anergy is associated with inability to gain weight despite 
microbiological cure.  Strategies targeted at reversal of this anergy could be a 
potential therapeutic approach in treatment of patients with sputum positive 
pulmonary tuberculosis.  
Delgado et al used intradermal injection of mumps and candida antigens in 
their study to validate the response obtained with PPD. This was not done in 
our study and remains a limitation while interpreting data on anergy. It is 
difficult to comment as to whether this is TB specific anergy or a generalized 
absence of delayed type hypersensitivity response. In a country like India with 
high prevalence of tuberculosis, PPD testing is not a useful indicator for ruling 
out active disease. This data re-iterates the fact that there are multiple factors 
determining PPD reactivity and this in isolation may not be enough even as an 
indicator of latent infection in adults.  
Routine assessment of PPD for all patients with tuberculosis will help us 
identify this subset of patients who are at high risk of adverse outcomes and 
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offer an intensified targeted approach with closer follow up and intensified 
nutritional regime. It’s a common understanding that PPD is old and redundant 
with no role in modern therapeutics or diagnostics. It’s time to change this 
thinking and delve more into PPD studies. We conclude that studies on PPD 
will help us understand the concept of overall and well-rounded recovery in 
patients diagnosed with Tuberculosis. 
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CONCLUSION 
In this study, about half the patients were found to be anergic (PPD  5mm) at 
baseline. Anergy to PPD was found to be significantly associated with chronic 
energy deficiency at baseline. Most patients had significant weight gain, 
increase in PPD reactivity and improvement in health related quality of life at 6 
months. A small subset of patients had persistent anergy. Persistent anergy was 
also associated with inability to gain weight. Patients who died during the study 
period were more likely to be anergic. However, the causal association remains 
unclear. Patients with past history of tuberculosis were also more likely to be 
anergic suggesting a higher risk of recurrence of the disease in these patients at 
a later point of time.  
The overall results do support an inter-relationship between 
undernutrition, cell mediated immunity, clinical improvement and quality 
of life at baseline and on therapy. Patients who are undernourished and 
have poor CMI have increased risk of death. Patients who fail to improve 
their nutrition also fail to improve their CMI. 
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LIMITATIONS 
1. The study had a large number of patients who were lost to follow up. 
Only 46 out of the 134 recruited at baseline completed the 6 months 
assessment.  
2. Micronutrient and macronutrient supplementation was planned for 
patients with chronic energy deficiency. However, this could not be 
done due to logistic constraints.  
3. Nutritional assessment and dietary recall were not performed by a 
qualified dietician.  
4. Intradermal instillation of comparator antigens was not performed 
making it difficult to ascertain whether the patients had a generalized 
lack of delayed type hypersensitivity or TB specific anergy.  
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Annexure 2 : Consent Form 
CORRELATION BETWEEN UNDERNUTRITION, CELL MEDIATED 
IMMUNE RESPONSE AND CLINICAL OUTCOMES IN PULMONARY 
TUBERCULOSIS: A HOSPITAL BASED LONGITUDINAL STUDY IN 
VELLORE, SOUTHERN INDIA 
 
 
Subject ID:  ____________ 
 
Subject’s Name: _________________________________________ 
 
Date of Birth (if available): 
 
Age (in completed years): ___________________________ 
 
 
(i)  I confirm that I have read and understood the information sheet dated January 
1st 2017 for the above study and have had the opportunity to ask questions. [  ] 
 
(ii)  I understand that my participation in the study is voluntary and that I amfree to 
withdraw at any time, without giving any reason, without my medical care or 
legal rights being affected. [  ] 
 
(iii)  I understand that the Sponsor of the clinical trial, others working on the 
Sponsor’s behalf, the Ethics Committee and the regulatory authorities will not 
need my permission to look at my health records both in respect of the current 
study and any further research that may be conducted in relation to it, even if I 
withdraw from the trial. I agree to this access. However, I understand that my 
identity will not be revealed in any information released to third parties or 
published. [  ] 
 
(iv)  I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s).[  ] 
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(v)  I agree to take part in the above study.[  ] 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable Representative 
 
Date: _____/_____/______ 
 
Witness : ________________________ 
 
Signatory’s Name: _________________________________Signature:  
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Annexure 3: Patient Information Sheet 
 
 
CORRELATION BETWEEN UNDERNUTRITION, CELL MEDIATED IMMUNE 
RESPONSE AND CLINICAL OUTCOMES IN PULMONARY TUBERCULOSIS: A 
HOSPITAL BASED LONGITUDINAL STUDY IN VELLORE, SOUTHERN INDIA 
 
Tuberculosis affects a large proportion of our population and despite continuing 
efforts to control the illness, it still remains a public health problem in our country. 
Tuberculosis in patients who are undernourished presents atypically with altered 
course and may result in adverse outcomes with delayed clearance of the organism. 
This is a serious form of the illness that can lead to disability and even death. Hence it 
is important to known more and more about this illness so that early diagnosis and 
treatment can be instituted. This study is aimed at finding out the relationship between 
nutritional status and a patient’s susceptibility to get sputum positive pulmonary 
tuberculosis. This study will also look at how the outcome differs in these patients 
with a change in nutritional status.   
 
You can ask questions for further information or doubts regarding the study following 
which you can opt to enrol yourself into this study. Following enrolment, 0.1 ml of a 
harmless protein will be injected into the skin (intra-dermal injection) at the time of 
initiation of treatment (ATT) and after six months of treatment. This is to measure 
your ability to resist and contain the infection. Also, height, weight and your mid arm 
circumference will be checked and if you are found to be under-nourished, a standard 
nutritional supplement will be provided for you for two months. Your treatment will 
not be altered in any form as a consequence of your participation in this study.  You 
will also be required to answer some questions regarding your health status at each 
visit to the hospital.  All information provided by you will be kept confidential and 
your identity will not be revealed to a third party under any circumstances.  
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By participating in this study, you will go a long way in helping the health care 
community better understand the mechanisms of the illness so that diagnosis can be 
made early and correct treatment be instituted in time to prevent the many 
complications of the disease. Any publications arising from the study will not have 
any patient identifiable data. You can opt out of the study, if you wish to do so, at any 
time. 
 
 
Thank you, 
 
Dr. Vijay Alexander 
Department of medicine 
Christian Medical College 
Vellore 
Phone: 96454 31265 
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Annexure 4: Data Extraction Form 
CORRELATION BETWEEN UNDERNUTRITION, CELL MEDIATED IMMUNE 
RESPONSE AND CLINICAL OUTCOMES IN PULMONARY TUBERCULOSIS: 
A HOSPITAL BASED LONGITUDINAL STUDY IN VELLORE, SOUTHERN 
INDIA 
1. Serial No :  
 
 
2. Name :_______________________________________ 
 
3. Hospital No:  
 
 
4. Age : _________ 
 
5. Date of Birth: __ /__/____ 
 
6. Address : 
 
__________________________________________________________ 
 
__________________________________________________________ 
 
__________________________________________________________ 
7.  Is this subject eligible for enrollment with respect to the residential address?       (If 
yes, proceed further. If no, thank and stop). 
 
7. Phone Number : ______________________________________ 
 
8. Occupation: _________________________ 
 
 
9. Date of Diagnosis of Tuberculosis: __/__/____ 
 
10. Type of Tuberculosis : Pulmonary / Disseminated 
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11. Have You Been Diagnosed to have Tuberculosis in the past? 
 
12. Have You Been Treated for Tuberculosis in the past? 
 
13. HIV Status : 
 
 
 
 
 
 
Assessment At Enrollment: 
 
1. Height : ___________cm. 
 
2. Weight :____________kg. 
 
3. BMI: _________________ 
 
4. Chronic Energy Deficiency Grade :  ____________ 
 
5. Skin Fold Thickness : Triceps - __________ 
 
6. Mid Upper Arm Circumference : _______________ 
 
7. Clinical assessment of macro and micronutrient deficiency 
a. Hair 
i. Lack of luster         : Yes / No 
ii. Depigmentation    : Yes /No 
iii. Flag Sign     : Yes / No 
b. Face – Nasolabial dys-sebacea   : Yes / No 
c. Eyes 
i. Pallor      : Yes / No 
ii. Bitot’s spots    : Yes / No 
iii. Conjunctival / Corneal Xerosis  : Yes / No 
d. Angular Stomatitis     : Yes / No 
e. Tongue 
i. Glossitis     :Yes / No 
ii. Balding of tongue with atrophic papillae : Yes / No 
f. Parotid Enlargement    : Yes / No 
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g. Skin  
i. Icthyosis    : Yes / No 
ii. Petechiae     : Yes / No 
iii. Perifollicular hemorrhages  :Yes / No 
h. Koilonychia     : Yes / No 
 
8. Hand Grip Strength  : Using Dynamometer  
a. Dominant Hand 
b. Non Dominant Hand 
 
 
9. Hemoglobin : ______________ g/dl. 
 
10. Albumin:______________ 
 
11. BBVS:_______________ 
 
12. Sputum AFB – Quantitate - ______________ 
 
 
13. Chest X Ray   
_______________________________________________________________
______________________ 
 
_______________________________________________________________
______________________ 
 
_______________________________________________________________
______________________ 
 
 
14. PPD Administered On ____________ (Date )At _____________ (Time). 
 
15. PPD Read on ___________________(Date) at ________________(Time). 
 
16. PPD Reading : Record Induration Measured in Mm ______________ 
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17. Quality of Life Questionnaire :  
 
 
 
 
 
Assessment at 2 months 
 
1. Weight  : ______________kg 
 
2. Quality of Life Questionnaire :  
 
 
 
 
 
3. Have you been compliant with therapy? _______________________ 
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4. How many days have you missed at least one drug in the last 2 months? 
_______________________________________________________________
_______________ 
 
5. Sputum AFB :  _________________________ 
 
 
Assessment at 6 months 
 
1. Height : ___________cm. 
 
2. Weight :____________kg. 
 
3. BMI: _________________ 
 
4. Chronic Energy Deficiency Grade :  ____________ 
 
5. Skin Fold Thickness : Triceps - __________ 
 
6. Mid Upper Arm Circumference : _______________ 
 
7. Clinical assessment of macro and micronutrient deficiency 
a. Hair 
i. Lack of luster         : Yes / No 
ii. Depigmentation    : Yes /No 
iii. Flag Sign     : Yes / No 
b. Face – Nasolabial dys-sebacea   : Yes / No 
c. Eyes 
i. Pallor      : Yes / No 
ii. Bitot’s spots    : Yes / No 
iii. Conjunctival / Corneal Xerosis  : Yes / No 
d. Angular Stomatitis     : Yes / No 
e. Tongue 
i. Glossitis     :Yes / No 
ii. Balding of tongue with atrophic papillae : Yes / No 
f. Parotid Enlargement    : Yes / No 
g. Skin  
i. Icthyosis    : Yes / No 
ii. Petechiae     : Yes / No 
iii. Perifollicular hemorrhages  :Yes / No 
h. Koilonychia     : Yes / No 
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8. Hand Grip Strength  : Using Dynamometer  
a. Dominant Hand 
b. Non Dominant Hand 
 
9. Hemoglobin : ______________ g/dl. 
 
10. Albumin:______________ 
 
11. Sputum AFB – Quantitate _______________ 
 
 
 
12. Chest X Ray   
_______________________________________________________________
______________________ 
 
_______________________________________________________________
______________________ 
 
13. PPD Administered On ____________ (Date )At _____________ (Time). 
 
14. PPD Read on ___________________(Date) at ________________(Time). 
 
 
15. PPD Reading : Record Induration Measured in Mm ______________ 
 
16. Quality of Life Questionnaire :  
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